Clinical Trials Directory

Trials / Sponsors / Clover Biopharmaceuticals AUS Pty

Clover Biopharmaceuticals AUS Pty

Industry · 16 registered clinical trials — 1 currently recruiting.

StatusTrialPhaseStarted
WithdrawnSafety and Immunogenicity Study of SCB-1019T in Children
RSV Infection
Phase 12025-10-01
RecruitingFirst-in-human Safety and Immunogenicity Study of SCB-1022 and SCB-1033 in Healthy Older Adults
Respiratory Syncytial Virus Vaccination, Human Metapneumovirus Vaccination, Parainfluenza Vaccination
Phase 12025-06-18
CompletedFirst-in-human Safety and Immunogenicity Study of SCB-1019 and SCB-1019T in Healthy Adults
Respiratory Syncytial Virus Vaccination
Phase 12023-12-13
WithdrawnImmunogenicity and Safety Study of Monovalent Omicron XBB.1.5 Vaccine as a Booster in Adults
COVID-19
Phase 32023-10-01
WithdrawnImmunogenicity and Safety Study of SCB-2023 Vaccine as a Booster in Adults
COVID-19
Phase 32023-08-17
WithdrawnSafety and Immunogenicity of SCB-2019 in Children <18 Years of Age
COVID-19
Phase 2 / Phase 32022-10-05
CompletedImmunogenicity and Safety Study of SCB-2019 Vaccine as a Booster to COVID-19 Vaccine in Adults
COVID-19
Phase 32022-06-13
CompletedSafety and Immunogenicity Dose-finding Study of Adjuvanted SCB-2020S Vaccine in Adults
COVID-19
Phase 12022-05-30
WithdrawnStudy of SCB-420 in Subjects With Neovascular Age-related Macular Degeneration
Wet Age-related Macular Degeneration
Phase 12022-04-01
TerminatedSafety and Immunogenicity of Adjuvanted SARS-CoV-2 (SCB-2019) Vaccine in Adults With Chronic Immune-Mediated D
COVID-19
Phase 32021-11-12
WithdrawnImmunogenicity and Safety of Adjuvanted SCB-2020S Vaccines in Adults
COVID-19
Phase 22021-08-01
CompletedA Controlled Phase 2/3 Study of Adjuvanted Recombinant SARS-CoV-2 Trimeric S-protein Vaccine (SCB-2019) for th
COVID-19
Phase 2 / Phase 32021-03-24
CompletedLong-term Follow-up to the Phase 1 Study of Adjuvanted SARS-CoV-2 (SCB 2019) Vaccine for COVID-19.
COVID-19
Phase 12021-01-19
CompletedSCB-2019 as COVID-19 Vaccine
COVID-19
Phase 12020-06-19
CompletedStudy With SCB-313 (Recombinant Human TRAIL-Trimer Fusion Protein) for Treatment of Malignant Pleural Effusion
Malignant Pleural Effusions
Phase 12019-11-20
CompletedStudy With SCB-313 (Recombinant Human TRAIL-Trimer Fusion Protein) for Treatment of Peritoneal Malignancies
Peritoneal Malignancies
Phase 12018-06-18